Literature DB >> 2679850

c-myc oncogene product expression and prognosis in operable breast cancer.

A P Locker1, C S Dowle, I O Ellis, C W Elston, R W Blamey, K Sikora, G Evan, R A Robins.   

Abstract

The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours. There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is important in the control of cellular differentiation. The other findings imply that measurement of c-myc oncoprotein levels does not yield useful prognostic information.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2679850      PMCID: PMC2247286          DOI: 10.1038/bjc.1989.337

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.

Authors:  M E Greenberg; E B Ziff
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

2.  Oncogenes.

Authors:  P Hamlyn; K Sikora
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

3.  The regulation of c-myc by growth signals.

Authors:  K Kelly; B Cochran; C Stiles; P Leder
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

4.  Expression of a cellular oncogene during liver regeneration.

Authors:  M Goyette; C J Petropoulos; P R Shank; N Fausto
Journal:  Science       Date:  1983-02-04       Impact factor: 47.728

5.  Differential expression of cellular oncogenes during pre- and postnatal development of the mouse.

Authors:  R Müller; D J Slamon; J M Tremblay; M J Cline; I M Verma
Journal:  Nature       Date:  1982-10-14       Impact factor: 49.962

6.  Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene.

Authors:  H Persson; P Leder
Journal:  Science       Date:  1984-08-17       Impact factor: 47.728

7.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.

Authors:  K Kelly; B H Cochran; C D Stiles; P Leder
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

9.  C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment.

Authors:  R Makino; K Hayashi; T Sugimura
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

10.  Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia.

Authors:  P Hendy-Ibbs; H Cox; G I Evan; J V Watson
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

View more
  8 in total

1.  Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses.

Authors:  Kristiina Joensuu; Jaana Hagström; Marjut Leidenius; Caj Haglund; Leif C Andersson; Hannu Sariola; Päivi Heikkilä
Journal:  Virchows Arch       Date:  2011-06-03       Impact factor: 4.064

Review 2.  Preoperative assessment of prognostic factors in breast cancer.

Authors:  H Denley; S E Pinder; C W Elston; A H Lee; I O Ellis
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

3.  The Nottingham Prognostic Index in primary breast cancer.

Authors:  M H Galea; R W Blamey; C E Elston; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Node negative breast cancer.

Authors:  R W Blamey; C W Elston; I O Ellis; D A Morgan; J L Haybittle
Journal:  BMJ       Date:  1990-04-28

5.  Lack of prognostic value of immunoreactivity for p62 oncoprotein in colorectal carcinoma.

Authors:  K Matsumoto; J Yamamoto; T Miura
Journal:  Int J Colorectal Dis       Date:  1993-07       Impact factor: 2.571

6.  Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Authors:  Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

7.  c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.

Authors:  G Sauter; P Carroll; H Moch; A Kallioniemi; R Kerschmann; P Narayan; M J Mihatsch; F M Waldman
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

8.  Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells.

Authors:  C Somay; T W Grunt; C Mannhalter; C Dittrich
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.